Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference

  Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013
                            Healthcare Conference

PR Newswire

ANAHEIM, Calif., May 8, 2013

ANAHEIM, Calif., May 8, 2013 /PRNewswire/ --Questcor Pharmaceuticals, Inc.
(NASDAQ: QCOR) announced today that executive management will present at the
Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas on May
14, 2013 at 4:20 PM PT/7:20 PM ET.

A live webcast and subsequent archived replay of the presentation will be
accessible at http://ir.questcor.com/events.cfm. The replay will be available
for approximately 90 days after the event.

About Questcor


Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Questcor also provides specialty contract
manufacturing services to the global pharmaceutical industry through its
wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P.
Acthar® Gel (repository corticotropin injection), an injectable drug that is
approved by the FDA for the treatment of 19 indications. Of these 19
indications, Questcor currently generates substantially all of its net sales
from the following on-label indications: the treatment of proteinuria in the
nephrotic syndrome of the idiopathic type, or NS, the treatment of acute
exacerbations of multiple sclerosis, or MS, in adults, the treatment of
infantile spasms, or IS, in infants and children under two years of age, and
the treatment of certain rheumatology related conditions, including the
treatment of the rare and closely related neuromuscular disorders
dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA
has approved Acthar to "induce a diuresis or a remission of proteinuria in the
nephrotic syndrome without uremia of the idiopathic type or that due to lupus
erythematosus." Questcor is also exploring the possibility of developing
markets for other on-label indications and the possibility of pursuing FDA
approval of additional indications not currently on the Acthar label where
there is high unmet medical need. For more information about Questcor, please
visit www.questcor.com. 

SOURCE Questcor Pharmaceuticals, Inc.

Website: http://www.questcor.com
Contact: EVC Group, Gregory Gin/Patty Eisenhaur, 646-445-4801/951-316-0577; or
Janine McCargo, 646-688-0425; or Doug Sherk, 415-652-9100
 
Press spacebar to pause and continue. Press esc to stop.